ALDX (STOCKS)
Aldeyra Therapeutics, Inc.
$1.810000
+0.030000 (+1.69%)
Prev close: $1.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Todd C. Brady
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $108.63M
- Employees
- 8
- P/E (TTM)
- -3.16
- P/B (TTM)
- 2.42
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
5
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.10 | $-0.17 | +0.0714 | +41.66% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.25 | +0.1199 | +47.98% |
|
Jun 2025 (Q2)
|
$-0.16 | $-0.25 | +0.0882 | +35.54% |
|
Mar 2025 (Q1)
|
$-0.17 | $-0.29 | +0.1156 | +40.48% |
Financial Statements
| Nonoperating Income/Loss | $1.42M |
| Research and Development | $25.66M |
| Operating Income/Loss | -$35.27M |
| Income/Loss From Continuing Operations After Tax | -$33.85M |
| Income/Loss From Continuing Operations Before Tax | -$33.85M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$33.85M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$33.85M |
| Net Income/Loss Available To Common Stockholders, Basic | -$33.85M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.56 |
| Diluted Earnings Per Share | -$0.56 |
| Basic Average Shares | 60,056,557 |
| Diluted Average Shares | 60,056,557 |
| Assets | $72.06M |
| Current Assets | $71.78M |
| Noncurrent Assets | $275.86K |
| Liabilities | $27.81M |
| Current Liabilities | $27.81M |
| Accounts Payable | $158.46K |
| Wages | $4.27M |
| Other Current Liabilities | $23.38M |
| Noncurrent Liabilities | $0.00 |
| Long-term Debt | $15.30M |
| Equity | $44.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $44.25M |
| Liabilities And Equity | $72.06M |
| Net Cash Flow From Operating Activities | -$33.35M |
| Net Cash Flow From Operating Activities, Continuing | -$33.35M |
| Net Cash Flow From Investing Activities | $47.74M |
| Net Cash Flow From Investing Activities, Continuing | $47.74M |
| Net Cash Flow From Financing Activities | $1.12M |
| Net Cash Flow From Financing Activities, Continuing | $1.12M |
| Net Cash Flow | $15.51M |
| Net Cash Flow, Continuing | $15.51M |
| Comprehensive Income/Loss | -$33.88M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$33.88M |
| Other Comprehensive Income/Loss | -$37.44K |
| Other Comprehensive Income/Loss Attributable To Parent | -$37.44K |